Diagnosis and treatment of hepatic encephalopathy in Spain: Results of a survey of hepatologists;Diagnóstico y tratamiento de la encefalopatía hepática en España: Resultados de una encuesta dirigida a hepatólogos

Gastroenterologia y Hepatologia

Volumn 29, Issue 1, 2006, Pages 1-6

  Vergara Gomez M ^a,b   Flavia Olivella M ^a   Gil Prades, M ^a   Dalmau Obrador, B ^a   Cordoba Cardona J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Servicio de Oncología Médica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DISACCHARIDE; DIURETIC AGENT; LACTULOSE; NEOMYCIN;

CLINICAL ASSESSMENT; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; NEUROPHYSIOLOGY; NUTRITION; PHYSICIAN; PROTEIN RESTRICTION; QUESTIONNAIRE; REVIEW; RISK FACTOR; SPAIN;

EID: 33644506185     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083245     Document Type: Article

References (36)

1. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-76.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-21.
3. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-Bt ML, Hop WC, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45-9.
4. Romero-Gomez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology. 2004;39:939-43.
5. Jover R, Company L, Gutierrez A, Zapater P, Perez-Serra J, Girona E, et al. Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. Am J Gastroenterol. 2003; 98:1599-604.
6. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890-5.
7. Blei AT. MARS y el tratamiento de la encefalopatía hepática. Gastroenterol Hepatol. 2005;28:100-4.
8. Fessel JN CHO. An analysis of the causes and prevention of hepatic coma. Gastroenterology. 1972;62:191-4.
9. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046-57.
10. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41: 38-43.
11. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005;365:431-3.
12. Plauth M, Merli M, Weimann A, Ferenci P, Mueller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clinical Nutrition. 1997;16:43-55.
13. Als-Nielsen B, Gluud L, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;CD003044.
14. Blei A. Encefalopatía hepática. En: Rodes J, editor. Tratado de Hepatología Clínica. Barcelona: Masson; 2005. p. 855-76.
15. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114:188-93.
16. Romero GM, Bautista JD, Grande L, Ramos Guerrero RM, Sanchez MD. New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects. Gastroenterol Hepatol. 2004;27 Suppl 1:40-8.
17. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs. 1997;53:930-42.
18. Sherlock S. Medical treatment of cirrhosis: general review. Union Med Can. 1974;103:2054-7.
19. Jalan R, Shawcross D, Davies N. The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol. 2003;35: 1175-81.
20. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology. 2002;36:1163-71.
21. Felipo V, Hermenegildo C, Montoliu C, Llansola M, Minana MD. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology. 1998;19:675-81.
22. Eriksson LS, Conn HO. Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology. 1989;10:228-46.
23. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol. 1990;11:92-101.
24. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792-801.
25. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247-54.
26. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125: 755-64.
27. Such J, Frances R, Munoz C, Zapater P, Casellas JA, Cifuentes A, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;36:135-41.
28. Haussinger D, Schliess F, Kircheis G. Pathogenesis of hepatic encephalopathy. J Gastroenterol Hepatol. 2002;17 Suppl 3: S256-S9.
29. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23:398-406.
30. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573-83.
31. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci. 1981;26:498-506.
32. Vargas VF, Campollo RO, Uribe EM, Lopez JF, Cervera CE. Knowledge, application, and diffusion of results of clinical research: the case of porto-systemic encephalopathy. Rev Gastroenterol Mex. 1992;57:191-8.
33. Pomier-Layrargues G, Giguere JF, Lavoie J, Perney P, Gagnon S, D'Amour M, et al. Flumazenilo in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology. 1994;19:32-7.
34. Goulenok C, Bernard B, Cadranel JF, Thabut D, Di M V, Opolon P, et al. Flumazenilo vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2002;16:361-72.
35. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16:531-5.
36. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718-23.